Annonce • Jun 30
Arrail Group Limited to Report Fiscal Year 2026 Results on Jun 30, 2026 Arrail Group Limited announced that they will report fiscal year 2026 results at 12:30 PM, China Standard Time on Jun 30, 2026 Annonce • Nov 18
Arrail Group Limited to Report First Half, 2026 Results on Nov 28, 2025 Arrail Group Limited announced that they will report first half, 2026 results on Nov 28, 2025 Annonce • Jun 28
Arrail Group Limited, Annual General Meeting, Sep 26, 2025 Arrail Group Limited, Annual General Meeting, Sep 26, 2025. Annonce • Jun 17
Arrail Group Limited to Report Fiscal Year 2025 Results on Jun 27, 2025 Arrail Group Limited announced that they will report fiscal year 2025 results on Jun 27, 2025 Annonce • Nov 19
Arrail Group Limited to Report Q2, 2025 Results on Nov 29, 2024 Arrail Group Limited announced that they will report Q2, 2025 results on Nov 29, 2024 Annonce • Sep 26
Arrail Group Limited Announces the Retirement of Xin Qin Jessie as Executive Director Arrail Group Limited announced that Ms. Xin Qin Jessie retired as an executive Director at the conclusion of the AGM held on September 26, 2024, in order to focus on her management commitment as the chief financial officer of the Group. Reported Earnings • Jul 28
Full year 2024 earnings released: EPS: CN¥0.037 (vs CN¥0.38 loss in FY 2023) Full year 2024 results: EPS: CN¥0.037 (up from CN¥0.38 loss in FY 2023). Revenue: CN¥1.75b (up 19% from FY 2023). Net income: CN¥17.2m (up CN¥237.1m from FY 2023). Profit margin: 1.0% (up from net loss in FY 2023). The move to profitability was driven by higher revenue. Revenue is forecast to grow 12% p.a. on average during the next 3 years, compared to a 3.7% growth forecast for the Healthcare industry in Germany. Recent Insider Transactions • Jul 05
Chairman of the Board & CEO recently bought €217k worth of stock On the 28th of June, Qifang Zou bought around 350k shares on-market at roughly €0.62 per share. This transaction amounted to less than 1% of their direct individual holding at the time of the trade. This was the largest purchase by an insider in the last 3 months. Qifang has been a buyer over the last 12 months, purchasing a net total of €451k worth in shares. Annonce • Jun 27
Arrail Group Limited, Annual General Meeting, Sep 26, 2024 Arrail Group Limited, Annual General Meeting, Sep 26, 2024. Reported Earnings • Jun 27
Full year 2024 earnings released: EPS: CN¥0.04 (vs CN¥0.38 loss in FY 2023) Full year 2024 results: EPS: CN¥0.04 (up from CN¥0.38 loss in FY 2023). Revenue: CN¥1.75b (up 19% from FY 2023). Net income: CN¥17.2m (up CN¥237.1m from FY 2023). Profit margin: 1.0% (up from net loss in FY 2023). The move to profitability was driven by higher revenue. Revenue is forecast to grow 11% p.a. on average during the next 3 years, compared to a 3.8% growth forecast for the Healthcare industry in Germany. Annonce • Jun 21
Arrail Group Limited Provides Earnings Guidance for the Fiscal Year Ended March 31, 2024 Arrail Group Limited provided earnings guidance for the fiscal year ended March 31, 2024. For the year, the Group is expected to record a net profit of no less than RMB 10.0 million for the fiscal year ended March 31, 2024, as compared to the net loss of approximately RMB 223.3 million for the fiscal year ended March 31, 2023. The expected profit is mainly attributable to revenue increase from business recovery after COVID-19 and the increase in the number of patient visits, especially the increased revenue generated from general dentistry, and operating improvement. Annonce • Jun 15
Arrail Group Limited to Report Fiscal Year 2024 Results on Jun 26, 2024 Arrail Group Limited announced that they will report fiscal year 2024 results on Jun 26, 2024 Recent Insider Transactions • May 02
Chairman of the Board & CEO recently bought €73k worth of stock On the 26th of April, Qifang Zou bought around 100k shares on-market at roughly €0.73 per share. This transaction amounted to less than 1% of their direct individual holding at the time of the trade. This was the largest purchase by an insider in the last 3 months. Qifang has been a buyer over the last 12 months, purchasing a net total of €228k worth in shares. Recent Insider Transactions • Dec 19
Chairman of the Board & CEO recently sold €4.8m worth of stock On the 12th of December, Qifang Zou sold around 3m shares on-market at roughly €1.56 per share. This transaction amounted to 4.4% of their direct individual holding at the time of the trade. This was the largest sale by an insider in the last 3 months. Qifang has been a net seller over the last 12 months, reducing personal holdings by €4.7m. Reported Earnings • Nov 30
First half 2024 earnings released: EPS: CN¥0.011 (vs CN¥0.15 loss in 1H 2023) First half 2024 results: EPS: CN¥0.011 (up from CN¥0.15 loss in 1H 2023). Revenue: CN¥886.2m (up 15% from 1H 2023). Net income: CN¥4.98m (up CN¥93.6m from 1H 2023). Profit margin: 0.6% (up from net loss in 1H 2023). The move to profitability was driven by higher revenue. Revenue is forecast to grow 13% p.a. on average during the next 3 years, compared to a 1.6% decline forecast for the Healthcare industry in Germany. Annonce • Nov 24
Arrail Group Limited Announces Unaudited Consolidated Earnings Guidance for the Six Months Ended September 30, 2023 The board (the "Board") of directors (the "Director(s)") of Arrail Group Limited announced that based on a preliminary review of the unaudited consolidated management accounts of the Group for the six months ended September 30, 2023 and assessment of the latest information currently available to the Board, the Group is expected to record a net profit of no less than RMB 5.0 million for the six months ended September 30, 2023, as compared to the net loss of approximately RMB 90.0 million for the six months ended September 30, 2022. The expected profit is mainly attributable to the business recovery after COVID-19 and operating improvement. Annonce • Nov 17
Arrail Group Limited to Report First Half, 2024 Results on Nov 28, 2023 Arrail Group Limited announced that they will report first half, 2024 results on Nov 28, 2023 New Risk • Oct 05
New major risk - Share price stability The company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of German stocks, typically moving 8.5% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. This is currently the only risk that has been identified for the company. Breakeven Date Change • Sep 26
Forecast breakeven date moved forward to 2024 The 3 analysts covering Arrail Group previously expected the company to break even in 2025. New consensus forecast suggests the company will make a profit of CN¥29.4m in 2024. Earnings growth of 94% is required to achieve expected profit on schedule. Reported Earnings • Jul 28
Full year 2023 earnings released: CN¥0.38 loss per share (vs CN¥8.70 loss in FY 2022) Full year 2023 results: CN¥0.38 loss per share (improved from CN¥8.70 loss in FY 2022). Revenue: CN¥1.47b (down 9.2% from FY 2022). Net loss: CN¥219.9m (loss narrowed 69% from FY 2022). Revenue is forecast to grow 19% p.a. on average during the next 3 years, compared to a 3.8% growth forecast for the Healthcare industry in Germany. Recent Insider Transactions • Jul 26
Chairman of the Board & CEO recently bought €164k worth of stock On the 19th of July, Qifang Zou bought around 200k shares on-market at roughly €0.82 per share. This transaction amounted to less than 1% of their direct individual holding at the time of the trade. This was the largest purchase by an insider in the last 3 months. Qifang has been a buyer over the last 12 months, purchasing a net total of €162k worth in shares. Breakeven Date Change • Jul 14
Forecast breakeven date pushed back to 2025 The 3 analysts covering Arrail Group previously expected the company to break even in 2024. New consensus forecast suggests losses will reduce by 96% to 2024. The company is expected to make a profit of CN¥84.9m in 2025. Average annual earnings growth of 104% is required to achieve expected profit on schedule. Annonce • Jun 28
Arrail Group Limited, Annual General Meeting, Sep 26, 2023 Arrail Group Limited, Annual General Meeting, Sep 26, 2023. Reported Earnings • Jun 28
Full year 2023 earnings released: CN¥0.38 loss per share (vs CN¥8.70 loss in FY 2022) Full year 2023 results: CN¥0.38 loss per share (improved from CN¥8.70 loss in FY 2022). Revenue: CN¥1.47b (down 9.2% from FY 2022). Net loss: CN¥219.9m (loss narrowed 69% from FY 2022). Revenue is forecast to grow 18% p.a. on average during the next 3 years, compared to a 4.1% growth forecast for the Healthcare industry in Germany. Annonce • Jun 15
Arrail Group Limited to Report Fiscal Year 2023 Results on Jun 27, 2023 Arrail Group Limited announced that they will report fiscal year 2023 results on Jun 27, 2023 Buying Opportunity • Apr 24
Now 32% undervalued Over the last 90 days, the stock is up 12%. The fair value is estimated to be €1.78, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has declined by 5.0% over the last year. Earnings per share has grown by 92%. Breakeven Date Change • Feb 28
Forecast breakeven date pushed back to 2024 The 3 analysts covering Arrail Group previously expected the company to break even in 2023. New consensus forecast suggests losses will reduce by 95% to 2023. The company is expected to make a profit of CN¥103.4m in 2024. Average annual earnings growth of 108% is required to achieve expected profit on schedule. Buying Opportunity • Feb 25
Now 21% undervalued Over the last 90 days, the stock is up 84%. The fair value is estimated to be €1.78, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has declined by 5.0% over the last year. Earnings per share has grown by 92%. Reported Earnings • Jan 01
First half 2023 earnings released: CN¥0.15 loss per share (vs CN¥5.89 loss in 1H 2022) First half 2023 results: CN¥0.15 loss per share (improved from CN¥5.89 loss in 1H 2022). Revenue: CN¥771.6m (down 8.3% from 1H 2022). Net loss: CN¥88.6m (loss narrowed 81% from 1H 2022). Revenue is forecast to grow 17% p.a. on average during the next 3 years, compared to a 4.5% growth forecast for the Healthcare industry in Germany. Reported Earnings • Nov 30
First half 2023 earnings released First half 2023 results: Revenue: CN¥771.6m (down 8.3% from 1H 2022). Net loss: CN¥88.6m (loss narrowed 81% from 1H 2022). Revenue is forecast to grow 17% p.a. on average during the next 3 years, compared to a 4.7% growth forecast for the Healthcare industry in Germany. Board Change • Nov 16
Less than half of directors are independent There are 5 new directors who have joined the board in the last 3 years. Of these new board members, 3 were independent directors. The company's board is composed of: 3 independent directors. 4 non-independent directors. Independent Non-Executive Director Michelle Liu was the last independent director to join the board, commencing their role in 2021. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Lack of board continuity. Reported Earnings • Jul 30
Full year 2022 earnings released: CN¥8.70 loss per share (vs CN¥8.21 loss in FY 2021) Full year 2022 results: CN¥8.70 loss per share (down from CN¥8.21 loss in FY 2021). Revenue: CN¥1.62b (up 7.2% from FY 2021). Net loss: CN¥701.0m (loss widened 17% from FY 2021). Over the next year, revenue is forecast to grow 19%, compared to a 3.8% growth forecast for the industry in Germany. Reported Earnings • Jun 29
Full year 2022 earnings released: CN¥8.70 loss per share (vs CN¥205 loss in FY 2021) Full year 2022 results: CN¥8.70 loss per share. Revenue: CN¥1.62b (up 7.2% from FY 2021). Net loss: CN¥701.0m (loss widened 17% from FY 2021). Over the next year, revenue is forecast to grow 22%, compared to a 4.3% growth forecast for the industry in Germany. Board Change • Apr 27
Less than half of directors are independent There are 5 new directors who have joined the board in the last 3 years. Of these new board members, 3 were independent directors. The company's board is composed of: 3 independent directors. 4 non-independent directors. Independent Non-Executive Director Michelle Liu was the last independent director to join the board, commencing their role in 2021. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Lack of board continuity. Board Change • Apr 12
Less than half of directors are independent There are 5 new directors who have joined the board in the last 3 years. Of these new board members, 3 were independent directors. The company's board is composed of: 3 independent directors. 4 non-independent directors. Independent Non-Executive Director Michelle Liu was the last independent director to join the board, commencing their role in 2021. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Lack of board continuity. 
